Cadonilimab - CAS 2394841-59-7

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8) . It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

PD-1/PD-L1, Immunology/Inflammation related, COX, IL Receptor

Neuroscience, Apoptosis, Immunology/Inflammation, Cell Cycle/Checkpoint

2394775

0.95

-20°C

Ice Packs

Inhibitory Antibodies